Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 35
Submit an article Journal homepage
3,608
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia

Jing-Zhou Hou1 University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center,Pittsburgh,PA15232,USACorrespondence[email protected]
View further author information
,
Kellie Ryan2 US Medical Affairs, AstraZeneca,Gaithersburg,MD20878,USAView further author information
,
Senxi Du3 Keck School of Medicine,Los Angeles,CA90033,USAView further author information
,
Bruno Fang4 Regional Cancer Care Associates,East Brunswick,NJ08816,USAView further author information
,
Stanley Marks1 University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center,Pittsburgh,PA15232,USAView further author information
,
Ray Page5 The Center of Cancer & Blood Disorders,Fort Worth,TX76104,USA;6 Quality Cancer Care Alliance Network,Tacoma,WA98405,USAView further author information
,
Eileen Peng4 Regional Cancer Care Associates,East Brunswick,NJ08816,USAView further author information
,
Keith Szymanski7 US Market Access, AstraZeneca,Gaithersburg,MD20878,USAView further author information
,
Sharon Winters1 University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center,Pittsburgh,PA15232,USAView further author information
&
Hannah Le2 US Medical Affairs, AstraZeneca,Gaithersburg,MD20878,USAView further author information
 show all
Pages 4959-4969 | Received 06 Aug 2021, Accepted 20 Oct 2021, Published online: 16 Nov 2021

References

  • Siegel RL , MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
  • Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am. J. Hematol.90(5), 446–460 (2015).
  • National Comprehensive Cancer Network . NCCN Clinical Practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma version 1.2022. National Comprehensive Cancer Network (2021). www.nccn.org/professionals/physician_gls/pdf/cll.pdf
  • Eichhorst B , RobakT, MontserratEet al. Chronic lymphocytic leukaemia: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.32(1), 23–33 (2021).
  • Introduction. In: SEER Cancer Statistics Review, 1975–2017.HowladerN, NooneAM, KrapchoMet al. ( et al. Eds). National Cancer Institute, MD, USA, 1–7 (2020).
  • Mato AR , BarrientosJC, GhoshNet al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL Registry. Clin. Lymphoma Myeloma Leuk.20(3), 174–183.e173 (2020).
  • Mato A , NabhanC, LamannaNet al. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv.4(7), 1407–1418 (2020).
  • Hallek M , FischerK, Fingerle-RowsonGet al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet376(9747), 1164–1174 (2010).
  • Goede V , FischerK, BuschRet al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med.370(12), 1101–1110 (2014).
  • Imbruvica [package insert]. Pharmacyclics, Janssen Biotech, Inc, PA, USA (2020). www.imbruvica.com/files/prescribing-information.pdf
  • Sharman JP , Black-ShinnJL, ClarkJ, BitmanB. Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia [abstract]. Blood130(Suppl. 1), 4060 (2017).
  • Hampel PJ , DingW, CallTGet al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk. Lymphoma60(11), 2712–2719 (2019).
  • Parikh SA , AchenbachSJ, CallTGet al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med.9(10), 3390–3399 (2020).
  • Burger JA , TedeschiA, BarrPMet al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med.373(25), 2425–2437 (2015).
  • Byrd JC , BrownJR, O’BrienSet al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med.371(3), 213–223 (2014).
  • Frei CR , LeH, McHughDet al. Treatment patterns and outcomes of 1205 patients on novel agents in the US Veterans Health Administration (VHA) System: results from the largest retrospective EMR and chart review study in the real-world setting [abstract]. Blood134(Suppl. 1), 795 (2019).
  • Hardy-Abeloos C , PinottiR, GabriloveJ. Ibrutinib dose modifications in the management of CLL. J. Hematol. Oncol.13(1), 66 (2020).
  • Dimou M , IliakisT, PardalisVet al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk. Lymphoma60(12), 2939–2945 (2019).
  • Mato AR , NabhanC, ThompsonMCet al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica103(5), 874–879 (2018).
  • Akhtar OS , AttwoodK, LundI, HareR, Hernandez-IlizaliturriFJ, TorkaP. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk. Lymphoma60(7), 1650–1655 (2019).
  • Burger JA , BarrPM, RobakTet al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia34(3), 787–798 (2020).
  • Huntington SF , SoulosPR, BarrPMet al. Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States [abstract]. Blood134(Suppl. 1), 797 (2019).
  • Iskierka-Jażdżewska E , HusM, GiannopoulosKet al. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leuk. Lymphoma58(10), 2485–2488 (2017).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.